Vaxart Announces $10.0 Million Registered Direct Offering Priced At-the-Market

NEXT STORY
Coherus BioSciences Reports Fourth Quarter and Full Year 2019 Financial Results
PREV STORY
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Fluid Management Systems Industry

author_avatar
NASDAQ Market News

EUROBIO SCIENTIFIC obtains CE marking for its proprietary test for Covid-19 screening and detection of the Omicron and Delta variants

author_avatar
NASDAQ Market News

Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

author_avatar
NASDAQ Market News